Crispr Therapeutics is trading 4.3% down at $53.37 after opening-market weakness on September 8, 2026, amid biotechnology-sector pressure following Novartis’s another late-stage trial failure.
- Citi said the setback could increase Crispr’s focus on next-generation CTX321.
- No direct Crispr-specific negative announcement was identified.
- Broader markets were mixed, limiting confidence in a purely macro explanation.